Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | CCKAR | P32238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933069 | 0.89 | HTR1A (0.42) | HTR1AKDM1ATDP1GRM5 | |
| SCHEMBL5273124 | 0.87 | KDM1A (0.40) | HTR1AKDM1ATDP1GRM5TACR3 | |
| SCHEMBL4932861 | 0.86 | HTR1A (0.42) | HTR1AKDM1ATDP1GRM5CHRNA7 | |
| SCHEMBL4934939 | 0.85 | CYP3A4 (0.40) | HTR1AKDM1ATDP1 | |
| SCHEMBL4931684 | 0.84 | KDM1A (0.43) | HTR1AKDM1ATDP1GRM5CHRNA7 | |
| SCHEMBL4931356 | 0.81 | MEN1 (0.41) | GRM5 | |
| SCHEMBL4931213 | 0.78 | CYP3A4 (0.40) | HTR1AKDM1AGRM5 | |
| SCHEMBL4929151 | 0.77 | KMT2A (0.42) | TDP1CHRNA7 | |
| SCHEMBL4932943 | 0.77 | ALDH1A1 (0.42) | KDM1AGRM5 | |
| SCHEMBL5524327 | 0.76 | CNR1 (0.38) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| CN-1980912-A | Pyrazole derivatives | DAIICHI SEIYAKU CO (JP) | 2007-06-13 | — | — | CN | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | HTR1A 362/4885KDM1A 559/4885TDP1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.